<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01603875</url>
  </required_header>
  <id_info>
    <org_study_id>RC5506</org_study_id>
    <nct_id>NCT01603875</nct_id>
  </id_info>
  <brief_title>Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV</brief_title>
  <official_title>Immune Response in Adults to Pre-exposure Rabies Vaccination and Simulated Post-exposure Rabies Booster Vaccination With a New Chromatographically Purified Vero-cell Rabies Vaccine(SPEEDA®) : a Randomized Controlled Trial With Purified Vero-cell Rabies Vaccine (PVRV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Saovabha Memorial Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen Saovabha Memorial Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre exposure rabies vaccination with a new Chromatographically Purified Vero-cell Rabies
      Vaccine(SPEEDA) is as effective as Purified Vero-cell Rabies vaccine.

      After the pre exposure rabies vaccination with a new Chromatographically Purified Vero-cell
      Rabies Vaccine(SPEEDA), the Rabies neutralizing antibodies in all patients on day 42 are 0.5
      IU/ml or more.

      And Simulated post-exposure rabies booster vaccination with a new Chromatographically
      Purified Vero-cell Rabies Vaccine(SPEEDA) is as effective as Purified Vero-cell Rabies
      vaccine.

      After the simulated post-exposure rabies booster vaccination with a new Chromatographically
      Purified Vero-cell Rabies Vaccine(SPEEDA), the Rabies neutralizing antibodies in all patients
      on day 14 after the booster are 0.5 IU/ml or more.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre-exposure vaccination will be done according to standard protocol. Participants will be
      injected with one dose on day 0, 7 and 28. Blood samples will be taken on day 0, 28 and 42
      after the first vaccination dose.

      360 days later, participants will receive simulated post-exposure rabies booster vaccination
      one dose on day 0 and 3. Blood samples will be taken again on day 0(360 days) and 14(374
      days) after the booster vaccination.

      Rabies neutralizing antibody levels will be measured by Rapid Fluorescent Focus Inhibition
      Test(RFFIT). And the levels of 0.5 IU/ml or more is considered acceptable protective level.

      For statistical analysis, percentage of subjects achieving seroconversion (defined as RNab ≥
      0.5 IU/ mL) are determine at each sampling time. The average of the titer used in this study
      is Geometric mean titer(GMT). 95 percent confidence interval(95% CI) of the GMT will be
      calculated for each study group from individual measurements of serum rabies antibody levels
      at each sampling time. One-way ANOVA would be used to calculated the significance of the
      difference between the GMT of three groups, SPEEDA® intradermal injection, SPEEDA®
      intramuscular injection and PVRV intramuscular injection. The primary criterion for this
      comparison are the rabies antibody value on day 42 (2 weeks after the third vaccine dose of
      pre-exposure vaccination) and on day 374(2 weeks after the first vaccine dose of booster
      vaccination). Results will be deemed statistically significant at p &lt; 0.05. Safety data
      (immediate, local and systemic reactions) were summarized as numbers and percentages.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT)</measure>
    <time_frame>on day 0</time_frame>
    <description>Blood samples will be drawn on day 0(After the first injection). The samples will be centrifuged and kept as serum under - 20 degree Celsius. The serum will be test by Rapid Florescent Focus Inhibition Test. Rabies neutralizing antibody levels will be determined and expressed in international units per mL. Percentage of Subjects achieving seroconversion (defined as RNab ≥ 0.5 IU/ mL) are determine at each sampling time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT)</measure>
    <time_frame>on day 28</time_frame>
    <description>Blood samples will be drawn on day 28(After the first injection). The samples will be centrifuged and kept as serum under - 20 degree Celsius. The serum will be test by Rapid Florescent Focus Inhibition Test. Rabies neutralizing antibody levels will be determined and expressed in international units per mL. Percentage of Subjects achieving seroconversion (defined as RNab ≥ 0.5 IU/ mL) are determine at each sampling time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT)</measure>
    <time_frame>on day 42</time_frame>
    <description>Blood samples will be drawn on day 42(After the first injection). The samples will be centrifuged and kept as serum under - 20 degree Celsius. The serum will be test by Rapid Florescent Focus Inhibition Test. Rabies neutralizing antibody levels will be determined and expressed in international units per mL. Percentage of Subjects achieving seroconversion (defined as RNab ≥ 0.5 IU/ mL) are determine at each sampling time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT)</measure>
    <time_frame>on day 360</time_frame>
    <description>Blood samples will be drawn on day 360(After the first injection). The samples will be centrifuged and kept as serum under - 20 degree Celsius. The serum will be test by Rapid Florescent Focus Inhibition Test. Rabies neutralizing antibody levels will be determined and expressed in international units per mL. Percentage of Subjects achieving seroconversion (defined as RNab ≥ 0.5 IU/ mL) are determine at each sampling time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT)</measure>
    <time_frame>on day 374</time_frame>
    <description>Blood samples will be drawn on day 374(After the first injection). The samples will be centrifuged and kept as serum under - 20 degree Celsius. The serum will be test by Rapid Florescent Focus Inhibition Test. Rabies neutralizing antibody levels will be determined and expressed in international units per mL. Percentage of Subjects achieving seroconversion (defined as RNab ≥ 0.5 IU/ mL) are determine at each sampling time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side Effects of the Vaccines. These Include Pain, Swelling, Redness, Myalgia, Rash, Fever. Serious Adverse Events Will Also be Recorded.</measure>
    <time_frame>up to 7 days after each injection</time_frame>
    <description>There are five injections, on day 0, 7, 28, 360 and 363.
The side effects will be record in number and percentage.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Efficacy of the New CPRV</condition>
  <arm_group>
    <arm_group_label>PrEP and Simulated PEP with PVRV by intramuscular route</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PrEP and Simulated PEP with new CPRV by intramuscular route</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PrEP and Simulated PEP with new CPRV by intradermal route</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).</intervention_name>
    <description>new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
    <arm_group_label>PrEP and Simulated PEP with PVRV by intramuscular route</arm_group_label>
    <arm_group_label>PrEP and Simulated PEP with new CPRV by intramuscular route</arm_group_label>
    <arm_group_label>PrEP and Simulated PEP with new CPRV by intradermal route</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Can visit according to the protocol

        Exclusion Criteria:

          -  Fever

          -  Acute illness

          -  History of rabies vaccination

          -  Allergic to the vaccines' component

          -  Immunosuppressive conditions such as HIV infection, transplantation, chronic renal
             failure, received steroid or immunosuppressive drugs and anti-malarial drugs within
             previous two months or any blood products within previous three months

          -  Female participant must not be pregnant

          -  All female participant must have urine pregnancy test negative prior to participate
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terapong Tantawichien, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Saovabha Memorial Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Saovabha Memorial Institute</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.saovabha.com/en/contactus.asp</url>
    <description>Contact information</description>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2012</study_first_submitted>
  <study_first_submitted_qc>May 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2012</study_first_posted>
  <results_first_submitted>January 3, 2014</results_first_submitted>
  <results_first_submitted_qc>January 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2014</results_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Saovabha Memorial Institute</investigator_affiliation>
    <investigator_full_name>Jaruboot Angsanakul, MD</investigator_full_name>
    <investigator_title>Jaruboot Angsanakul, Medical Officer 4</investigator_title>
  </responsible_party>
  <keyword>CPRV</keyword>
  <keyword>SPEEDA</keyword>
  <keyword>intradermal</keyword>
  <keyword>pre-exposure</keyword>
  <keyword>booster</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We recruited 66 subjects from Faculty of Veterinarian, Chulalongkorn University. The recruitment held between June 25, 2012 and July 2, 2012. Others 39 subjects was recruited from Faculty of Veterinarian, Mahanakorn University of Technology.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PrEP and Simulated PEP With PVRV by Intramuscular Route</title>
          <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
        </group>
        <group group_id="P2">
          <title>PrEP and Simulated PEP With New CPRV by Intramuscular Route</title>
          <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
        </group>
        <group group_id="P3">
          <title>PrEP and Simulated PEP With New CPRV by Intradermal Route</title>
          <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Preexisting rabies antibody</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PrEP and Simulated PEP With PVRV by Intramuscular Route</title>
          <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
        </group>
        <group group_id="B2">
          <title>PrEP and Simulated PEP With New CPRV by Intramuscular Route</title>
          <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
        </group>
        <group group_id="B3">
          <title>PrEP and Simulated PEP With New CPRV by Intradermal Route</title>
          <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.96" spread="1.138"/>
                    <measurement group_id="B2" value="20.04" spread="5.633"/>
                    <measurement group_id="B3" value="18.92" spread="0.744"/>
                    <measurement group_id="B4" value="19.31" spread="3.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT)</title>
        <description>Blood samples will be drawn on day 0(After the first injection). The samples will be centrifuged and kept as serum under - 20 degree Celsius. The serum will be test by Rapid Florescent Focus Inhibition Test. Rabies neutralizing antibody levels will be determined and expressed in international units per mL. Percentage of Subjects achieving seroconversion (defined as RNab ≥ 0.5 IU/ mL) are determine at each sampling time.</description>
        <time_frame>on day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PrEP and Simulated PEP With PVRV by Intramuscular Route</title>
            <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
          </group>
          <group group_id="O2">
            <title>PrEP and Simulated PEP With New CPRV by Intramuscular Route</title>
            <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
          </group>
          <group group_id="O3">
            <title>PrEP and Simulated PEP With New CPRV by Intradermal Route</title>
            <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT)</title>
          <description>Blood samples will be drawn on day 0(After the first injection). The samples will be centrifuged and kept as serum under - 20 degree Celsius. The serum will be test by Rapid Florescent Focus Inhibition Test. Rabies neutralizing antibody levels will be determined and expressed in international units per mL. Percentage of Subjects achieving seroconversion (defined as RNab ≥ 0.5 IU/ mL) are determine at each sampling time.</description>
          <units>International unit per ml</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT)</title>
        <description>Blood samples will be drawn on day 28(After the first injection). The samples will be centrifuged and kept as serum under - 20 degree Celsius. The serum will be test by Rapid Florescent Focus Inhibition Test. Rabies neutralizing antibody levels will be determined and expressed in international units per mL. Percentage of Subjects achieving seroconversion (defined as RNab ≥ 0.5 IU/ mL) are determine at each sampling time.</description>
        <time_frame>on day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PrEP and Simulated PEP With PVRV by Intramuscular Route</title>
            <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
          </group>
          <group group_id="O2">
            <title>PrEP and Simulated PEP With New CPRV by Intramuscular Route</title>
            <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
          </group>
          <group group_id="O3">
            <title>PrEP and Simulated PEP With New CPRV by Intradermal Route</title>
            <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT)</title>
          <description>Blood samples will be drawn on day 28(After the first injection). The samples will be centrifuged and kept as serum under - 20 degree Celsius. The serum will be test by Rapid Florescent Focus Inhibition Test. Rabies neutralizing antibody levels will be determined and expressed in international units per mL. Percentage of Subjects achieving seroconversion (defined as RNab ≥ 0.5 IU/ mL) are determine at each sampling time.</description>
          <units>International unit per ml</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" lower_limit="0.57" upper_limit="11.81"/>
                    <measurement group_id="O2" value="4.23" lower_limit="0.46" upper_limit="19.03"/>
                    <measurement group_id="O3" value="1.83" lower_limit="0.16" upper_limit="17.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT)</title>
        <description>Blood samples will be drawn on day 42(After the first injection). The samples will be centrifuged and kept as serum under - 20 degree Celsius. The serum will be test by Rapid Florescent Focus Inhibition Test. Rabies neutralizing antibody levels will be determined and expressed in international units per mL. Percentage of Subjects achieving seroconversion (defined as RNab ≥ 0.5 IU/ mL) are determine at each sampling time.</description>
        <time_frame>on day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PrEP and Simulated PEP With PVRV by Intramuscular Route</title>
            <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
          </group>
          <group group_id="O2">
            <title>PrEP and Simulated PEP With New CPRV by Intramuscular Route</title>
            <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
          </group>
          <group group_id="O3">
            <title>PrEP and Simulated PEP With New CPRV by Intradermal Route</title>
            <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT)</title>
          <description>Blood samples will be drawn on day 42(After the first injection). The samples will be centrifuged and kept as serum under - 20 degree Celsius. The serum will be test by Rapid Florescent Focus Inhibition Test. Rabies neutralizing antibody levels will be determined and expressed in international units per mL. Percentage of Subjects achieving seroconversion (defined as RNab ≥ 0.5 IU/ mL) are determine at each sampling time.</description>
          <units>International unit per ml</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.49" lower_limit="2.38" upper_limit="51.54"/>
                    <measurement group_id="O2" value="14.23" lower_limit="1.83" upper_limit="64.00"/>
                    <measurement group_id="O3" value="5.02" lower_limit="0.59" upper_limit="26.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT)</title>
        <description>Blood samples will be drawn on day 360(After the first injection). The samples will be centrifuged and kept as serum under - 20 degree Celsius. The serum will be test by Rapid Florescent Focus Inhibition Test. Rabies neutralizing antibody levels will be determined and expressed in international units per mL. Percentage of Subjects achieving seroconversion (defined as RNab ≥ 0.5 IU/ mL) are determine at each sampling time.</description>
        <time_frame>on day 360</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PrEP and Simulated PEP With PVRV by Intramuscular Route</title>
            <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
          </group>
          <group group_id="O2">
            <title>PrEP and Simulated PEP With New CPRV by Intramuscular Route</title>
            <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
          </group>
          <group group_id="O3">
            <title>PrEP and Simulated PEP With New CPRV by Intradermal Route</title>
            <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT)</title>
          <description>Blood samples will be drawn on day 360(After the first injection). The samples will be centrifuged and kept as serum under - 20 degree Celsius. The serum will be test by Rapid Florescent Focus Inhibition Test. Rabies neutralizing antibody levels will be determined and expressed in international units per mL. Percentage of Subjects achieving seroconversion (defined as RNab ≥ 0.5 IU/ mL) are determine at each sampling time.</description>
          <units>International unit per ml</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" lower_limit="0.16" upper_limit="1.83"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.13" upper_limit="3.67"/>
                    <measurement group_id="O3" value="0.28" lower_limit="0.07" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT)</title>
        <description>Blood samples will be drawn on day 374(After the first injection). The samples will be centrifuged and kept as serum under - 20 degree Celsius. The serum will be test by Rapid Florescent Focus Inhibition Test. Rabies neutralizing antibody levels will be determined and expressed in international units per mL. Percentage of Subjects achieving seroconversion (defined as RNab ≥ 0.5 IU/ mL) are determine at each sampling time.</description>
        <time_frame>on day 374</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PrEP and Simulated PEP With PVRV by Intramuscular Route</title>
            <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
          </group>
          <group group_id="O2">
            <title>PrEP and Simulated PEP With New CPRV by Intramuscular Route</title>
            <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
          </group>
          <group group_id="O3">
            <title>PrEP and Simulated PEP With New CPRV by Intradermal Route</title>
            <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT)</title>
          <description>Blood samples will be drawn on day 374(After the first injection). The samples will be centrifuged and kept as serum under - 20 degree Celsius. The serum will be test by Rapid Florescent Focus Inhibition Test. Rabies neutralizing antibody levels will be determined and expressed in international units per mL. Percentage of Subjects achieving seroconversion (defined as RNab ≥ 0.5 IU/ mL) are determine at each sampling time.</description>
          <units>International unit per ml</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.16" lower_limit="7.66" upper_limit="112.40"/>
                    <measurement group_id="O2" value="45.99" lower_limit="4.36" upper_limit="693.38"/>
                    <measurement group_id="O3" value="11.93" lower_limit="3.22" upper_limit="66.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects of the Vaccines. These Include Pain, Swelling, Redness, Myalgia, Rash, Fever. Serious Adverse Events Will Also be Recorded.</title>
        <description>There are five injections, on day 0, 7, 28, 360 and 363.
The side effects will be record in number and percentage.</description>
        <time_frame>up to 7 days after each injection</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>42 days since the first dose was administered. One year later, 14 days since the first booster dose was administered.</time_frame>
      <desc>Pain, pruritus, erythema, induration, fever, urticaria, arthralgia, myalgia, dizziness, headache, nausea, vomiting, lymphadenopathy were recorded.</desc>
      <group_list>
        <group group_id="E1">
          <title>PrEP and Simulated PEP With PVRV by Intramuscular Route</title>
          <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
        </group>
        <group group_id="E2">
          <title>PrEP and Simulated PEP With New CPRV by Intramuscular Route</title>
          <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
        </group>
        <group group_id="E3">
          <title>PrEP and Simulated PEP With New CPRV by Intradermal Route</title>
          <description>New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="149" subjects_affected="28" subjects_at_risk="35"/>
                <counts group_id="E2" events="147" subjects_affected="27" subjects_at_risk="35"/>
                <counts group_id="E3" events="148" subjects_affected="15" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E3" events="38" subjects_affected="16" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>induration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Terapong Tantawichien</name_or_title>
      <organization>Queen Saovabha Memorial Institute</organization>
      <phone>66225201614 ext 125</phone>
      <email>terapong_tantawichien@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

